ESR1 and breast carcinoma: While those studies have highlighted the importance of heterogeneity by age (at treatment initiation) and tumour stage, no study has also investigated the cost-effectiveness by estrogen receptor (ER) and progesterone receptor (PR) status in early stage HER2+ breast cancer.